Medical Study Results
- In a medical study, 2 out of 3 patients treated with STELARA™ saw at least 75% skin clearance at 12 weeks.
- In another study, skin clearance was maintained at one year in most patients who initially responded to STELARA™ and continued to receive treatment.
- In both studies, treatment with STELARA™ helped provide relief from the symptoms associated with psoriatic plaques, such as plaque thickness, scaling and redness.
Individual results may vary.
For illustrative purposes only.
Individual results may vary.
To study safety and effectiveness, STELARA™ has been tested in over 2,200 patients in medical studies. The safety and effectiveness of STELARA™ have not been evaluated beyond two years. Changes in patients' plaque psoriasis symptoms and any side effects were closely observed.
STELARA™ is approved to treat adults 18 years and older with moderate or severe psoriasis that involves large areas or many areas of their body, who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).
Read more about the safety of STELARA.™
How STELARA™ Targets an Underlying Cause of Psoriasis
An overactive immune system can lead to high levels of IL-12 and IL-23, two proteins that have been found in psoriatic skin plaques. STELARA,™ a biologic medicine, binds to IL-12 and IL-23. By preventing these two proteins from attaching to cells in your body, STELARA™ slows down the production of skin cells and helps reduce inflammation.
STELARA™ may improve your psoriasis but may also lower the ability of your immune system to fight infections and may increase your risk of serious infection. STELARA™ may also increase your risk for certain types of cancer.
Dosing
STELARA™ is an injection under the skin that should only be given by a healthcare provider as directed by your doctor. Your doctor will choose the right dose of STELARA™ for you and how often you will receive it. Make sure you keep all your scheduled follow-up appointments.
